alexa Altered Vaccine Immune Responses To Different Toll-Like Receptor Activators
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

16th Euro Global Summit and Expo on Vaccines & Vaccination
June 19-21, 2017 Paris, France

Kei Amemiya
US Army Medical Research Institute of Infectious Diseases, USA
Keynote: J Vaccines Vaccin
DOI: 10.4172/2157-7560-C1-056
Abstract
Although it has been demonstrated that vaccination can protect the health of certain populations against specific pathogens, the creation of an effective vaccine against threating diseases is not always easily obtainable. An example of this can be applied to a vaccine against Yersinia pestis, is the pathogen that causes plague and has killed millions of people throughout the ages. There are three clinical presentations of plague: septicemic, bubonic and pneumonic. The latter form of the disease is the most severe because it is almost 100% fatal without immediate medical treatment. It has been only a little over 100 years that Y. pestis was identified as the etiological agent that caused plague, and another 100 years before a potential safe vaccine candidate for human use has been tentatively identified. In between these two discoveries, an inactivated whole-cell vaccine was used against plague, albeit with limited efficacy. The use of a formalin-inactivated, whole cell vaccine had been discontinued in the midnineties because it was apparently not protective against the pneumonic form of the disease which is the most deadly form of plague. In addition, the inactivated whole cell vaccine was very immunoreactive and considered not safe for human use. The current plague vaccine candidate consists of two pathogen proteins: a capsule protein (F1), and a virulence protein (V-antigen). It has been shown to be efficacious in both mouse and nonhuman primate models of pneumonic plague, and the vaccine has been through two human clinical trials. Nonetheless, efforts are still being undertaken to enhance the immune properties of the vaccine so that it can provide a more robust protective response against the disease. We will present examples of some of the efforts to achieve these goals for the latest vaccine candidate.
Biography

Kei Amemiya received his Doctoral degree from Rutgers University in Microbiology in 1973. He did his Post-graduation studies in Gene Regulation in the Laboratory of Lucy Shapiro at Albert Einstein College of Medicine, Bronx, NY. He joined the National Institute of Neurological Diseases and Stroke in 1986, where he examined gene regulation in JC virus that caused the demyelinating disease progressive multifocal leukoencephalopathy in immune suppressed patients. In 1999, he went to the US Army Medical Research Institute of Infectious Diseases, Bacteriology Division, where he has been involved in vaccine development for Burkholderia mallei and Yersinia pestis. His primary interest has been in the immune response and innate immunity in animal models.

Email: [email protected]

image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords